Soleno Therapeutics Inc (SLNO)
42.41
-2.61
(-5.80%)
USD |
NASDAQ |
Jun 14, 16:00
42.56
+0.15
(+0.35%)
After-Hours: 20:00
Soleno Therapeutics Enterprise Value: 1.414B for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | 1.414B |
| June 13, 2024 | 1.510B |
| June 12, 2024 | 1.552B |
| June 11, 2024 | 1.562B |
| June 10, 2024 | 1.585B |
| June 07, 2024 | 1.530B |
| June 06, 2024 | 1.496B |
| June 05, 2024 | 1.493B |
| June 04, 2024 | 1.361B |
| June 03, 2024 | 1.421B |
| May 31, 2024 | 1.401B |
| May 30, 2024 | 1.422B |
| May 29, 2024 | 1.431B |
| May 28, 2024 | 1.354B |
| May 24, 2024 | 1.368B |
| May 23, 2024 | 1.368B |
| May 22, 2024 | 1.431B |
| May 21, 2024 | 1.482B |
| May 20, 2024 | 1.583B |
| May 17, 2024 | 1.552B |
| May 16, 2024 | 1.533B |
| May 15, 2024 | 1.517B |
| May 14, 2024 | 1.454B |
| May 13, 2024 | 1.428B |
| May 10, 2024 | 1.509B |
| Date | Value |
|---|---|
| May 09, 2024 | 1.606B |
| May 08, 2024 | 1.556B |
| May 07, 2024 | 1.575B |
| May 06, 2024 | 1.385B |
| May 03, 2024 | 1.358B |
| May 02, 2024 | 1.495B |
| May 01, 2024 | 1.439B |
| April 30, 2024 | 1.343B |
| April 29, 2024 | 1.372B |
| April 26, 2024 | 1.116B |
| April 25, 2024 | 1.098B |
| April 24, 2024 | 1.165B |
| April 23, 2024 | 1.192B |
| April 22, 2024 | 1.105B |
| April 19, 2024 | 1.103B |
| April 18, 2024 | 1.092B |
| April 17, 2024 | 1.117B |
| April 16, 2024 | 1.113B |
| April 15, 2024 | 1.137B |
| April 12, 2024 | 1.089B |
| April 11, 2024 | 1.150B |
| April 10, 2024 | 1.122B |
| April 09, 2024 | 1.220B |
| April 08, 2024 | 1.194B |
| April 05, 2024 | 1.244B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-12.47M
Minimum
Dec 15 2022
1.606B
Maximum
May 09 2024
200.50M
Average
46.16M
Median
Jul 13 2021
Enterprise Value Benchmarks
| SINTX Technologies Inc | -2.566M |
| Phibro Animal Health Corp | 1.085B |
| Avenue Therapeutics Inc | -0.6409M |
| Deciphera Pharmaceuticals Inc | 1.940B |
| Flora Growth Corp | 13.02M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.40M |
| Total Expenses (Quarterly) | 23.07M |
| EPS Diluted (Quarterly) | -0.59 |
| Earnings Yield | -6.38% |
| Normalized Earnings Yield | -163.22 |